ATE421976T1 - Fab fragmentbibliotheken und verfahren für deren verwendung - Google Patents

Fab fragmentbibliotheken und verfahren für deren verwendung

Info

Publication number
ATE421976T1
ATE421976T1 AT99201558T AT99201558T ATE421976T1 AT E421976 T1 ATE421976 T1 AT E421976T1 AT 99201558 T AT99201558 T AT 99201558T AT 99201558 T AT99201558 T AT 99201558T AT E421976 T1 ATE421976 T1 AT E421976T1
Authority
AT
Austria
Prior art keywords
methods
fab fragment
fragment libraries
fab
libraries
Prior art date
Application number
AT99201558T
Other languages
English (en)
Inventor
Hendricus Renerus Jacobus Hoogenboom
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of ATE421976T1 publication Critical patent/ATE421976T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99201558T 1999-05-18 1999-05-18 Fab fragmentbibliotheken und verfahren für deren verwendung ATE421976T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99201558A EP1054018B1 (de) 1999-05-18 1999-05-18 Fab Fragmentbibliotheken und Verfahren für deren Verwendung

Publications (1)

Publication Number Publication Date
ATE421976T1 true ATE421976T1 (de) 2009-02-15

Family

ID=8240210

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99201558T ATE421976T1 (de) 1999-05-18 1999-05-18 Fab fragmentbibliotheken und verfahren für deren verwendung

Country Status (10)

Country Link
EP (2) EP2067788B1 (de)
JP (3) JP4741086B2 (de)
AT (1) ATE421976T1 (de)
AU (1) AU780145B2 (de)
CA (1) CA2372582C (de)
DE (1) DE69940364D1 (de)
DK (2) DK2067788T3 (de)
ES (2) ES2549440T3 (de)
PT (2) PT1054018E (de)
WO (1) WO2000070023A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60237704D1 (de) 2001-10-16 2010-10-28 Government Of The Us Secretary Neutralisierende antikörper gegen hiv mit breiter kreuzreaktion, die mit hilfe von env-cd4-co-rezeptorkomplexen selektiert werden
CA2485120C (en) 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
EP1554392A4 (de) * 2002-05-06 2007-08-08 Us Gov Health & Human Serv Identifizierung neuer neutralisierender menschlicher monoklonaler antikörper mit breiter kreuzreaktivität unter verwendung eines sequentiellen antigen-panning von phagen-display-bibliotheken
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
ES2360291T3 (es) 2003-03-07 2011-06-02 New England Medical Center Hospitals, Inc. TRATAMIENTO DE ENFERMEDADES POR DEPOSICIÓN DE IgA1.
US7157562B1 (en) * 2003-04-14 2007-01-02 The United States Of America As Represented By The Secretary Of The Army Bioprocess for the production of recombinant anti-botulinum toxin antibody
EP2395016A3 (de) 2003-05-30 2012-12-19 Merus B.V. Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1704251A1 (de) * 2003-12-15 2006-09-27 Institut Pasteur Repertoirbestimmung einer b-lymphozytenpopulation
EP2990053A1 (de) 2004-01-20 2016-03-02 KaloBios Pharmaceuticals, Inc. Antikörper-spezifitätstransfer mit minimal essenziell bindenden determinanten
JP5912211B2 (ja) 2004-01-20 2016-04-27 メルス ビー．ヴィー． 結合タンパク質の混合物
PT1735348E (pt) 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1707628B1 (de) * 2005-03-30 2009-11-11 Sekisui Chemical Co., Ltd. Verfahren zur Produktion von rekombinanten polyklonalen Immunglobulinen
CN101548034B (zh) * 2006-10-02 2013-11-13 航道生物技术有限责任公司 多样性合成肽和多肽文库的设计和构建
CN101126760B (zh) * 2007-01-17 2011-11-16 江苏省人民医院 全人源抗卵泡刺激素β单链抗体筛选方法及其用途
EP2537931B1 (de) * 2010-02-19 2016-10-19 Japan Science And Technology Agency Antivirales abzym
CA2833404A1 (en) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
WO2013045632A1 (en) 2011-09-28 2013-04-04 Era Biotech, S.A. Split inteins and uses thereof
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
PH12017501834B1 (en) 2015-04-06 2024-01-17 Arcellx Inc De novo binding domain containing polypeptides and uses thereof
ES2837482T3 (es) * 2016-04-06 2021-06-30 Zumutor Biologics Inc Vectores para la clonación y expresión de proteínas, métodos y aplicaciones de estos
US20190324030A1 (en) 2016-06-27 2019-10-24 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
MA45455A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées
CA3058290A1 (en) 2017-04-18 2018-10-25 Universite Libre De Bruxelles Biomarkers and targets for proliferative diseases
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
MX2020004933A (es) 2017-11-14 2021-01-08 Arcellx Inc Polipéptidos que contienen dominios d y sus usos.
EP3768701B1 (de) 2018-03-23 2023-08-02 Université Libre de Bruxelles Agonistenmoleküle des wnt-signalwegs
CA3106115A1 (en) 2018-07-08 2020-01-16 Specifica Inc. Antibody libraries with maximized antibody developability characteristics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4518564A (en) 1983-10-03 1985-05-21 Jeneric Industries, Inc. Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
FI915411A0 (fi) * 1989-05-16 1991-11-15 Scripps Research Inst Samexpression av heteromeriska receptorer.
AU635844B2 (en) 1989-11-06 1993-04-01 Cell Genesys, Inc. Production of proteins using homologous recombination
US5126323A (en) 1989-11-16 1992-06-30 Genetics Institute, Inc. Homogeneous purified k-fgf and compositions containing the same
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
DE4005633A1 (de) 1990-02-22 1991-08-29 Schuetz Werke Gmbh Co Kg Palettenbehaelter
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE414768T1 (de) * 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
EP0663953B1 (de) * 1992-09-04 2001-12-05 The Scripps Research Institute Phagemiden die einen oberflächenrezeptor und ein heterologes oberflächenprotein co-exprimieren
EP1347493A3 (de) 1993-05-28 2005-11-23 Baylor College Of Medicine Verfahren und Gerät zur Desorption und Ionisierung von Analyte
CA2169191C (en) 1993-08-26 2008-01-15 Elizabeth A. Wang Neural regeneration using human bone morphogenetic proteins
AU689184B2 (en) 1993-12-07 1998-03-26 Genetics Institute, Llc BMP-12, BMP-13 and tendon-inducing compositions thereof

Also Published As

Publication number Publication date
CA2372582A1 (en) 2000-11-23
JP2010273689A (ja) 2010-12-09
AU780145B2 (en) 2005-03-03
WO2000070023A9 (en) 2002-01-17
EP2067788A2 (de) 2009-06-10
ES2321568T3 (es) 2009-06-08
JP2013078315A (ja) 2013-05-02
HK1134303A1 (en) 2010-04-23
JP5159841B2 (ja) 2013-03-13
AU5142200A (en) 2000-12-05
EP1054018B1 (de) 2009-01-28
DE69940364D1 (de) 2009-03-19
CA2372582C (en) 2013-08-13
DK2067788T3 (da) 2015-10-19
PT1054018E (pt) 2009-02-16
JP2002543830A (ja) 2002-12-24
PT2067788E (pt) 2015-10-29
DK1054018T3 (da) 2009-05-18
JP4741086B2 (ja) 2011-08-03
EP1054018A1 (de) 2000-11-22
EP2067788B1 (de) 2015-07-22
EP2067788A3 (de) 2010-04-21
ES2549440T3 (es) 2015-10-28
WO2000070023A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
ATE421976T1 (de) Fab fragmentbibliotheken und verfahren für deren verwendung
NO2006008I1 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
DK0933082T3 (da) Fremgangsmåde til manipulation af celledifferentiering
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
NZ334226A (en) Humanized immunoglobulin reactive with alpha 4 beta 7 integrin
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
ATE283926T1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
CY1111966T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0722ρ και μεθοδοι χρησεις αυτων
TW200516083A (en) Methods for making dual specificity antibodies
ATE531812T1 (de) Humanisierung von nager-antikörpern
CY1108663T1 (el) Αναστολεις της ενεργοποιησης συμπληρωματος
DK1325033T3 (da) Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
ATE178097T1 (de) Monoklonale antikörper gegen den alpha-pdgf- rezeptor und deren verwendungen
IT1271461B (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
DK0868427T3 (da) Fremgangsmåder til at idenficere forbindelser, der binder til et mål
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE312622T1 (de) Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin
ATE229037T1 (de) Monoklonaler antikörper gegen denthrombin- antithrombin iii-komplex und dessen verwendung in immunoassays
NO20004251D0 (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
FR2710068B1 (fr) Dérivés de nucléosides, procédés de fabrication de ces dérivés de nucléosides et anticorps polyclonaux et monoclonaux spécifiques de ces dérivés.
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
CY1116268T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0772ρ και μεθοδοι χρησεις αυτων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1054018

Country of ref document: EP